Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/29943
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wranke, Anika | - |
dc.contributor.author | Hardtke, Svenja | - |
dc.contributor.author | Heidrich, Benjamin | - |
dc.contributor.author | Dalekos, George | - |
dc.contributor.author | Yalçın, Kendal | - |
dc.contributor.author | Tabak, Fehmi | - |
dc.contributor.author | Çakaloğlu, Yılmaz | - |
dc.contributor.author | Akarca, Ulus S. | - |
dc.contributor.author | Lammert, Frank | - |
dc.contributor.author | Haeussinger, Dieter | - |
dc.contributor.author | Mueller, Tobias | - |
dc.contributor.author | Woebse, Michael | - |
dc.contributor.author | Manns, Michael P. | - |
dc.contributor.author | Idilman, Ramazan | - |
dc.contributor.author | Cornberg, Markus | - |
dc.contributor.author | Wedemeyer, Heiner | - |
dc.contributor.author | Yurdaydın, Cihan | - |
dc.date.accessioned | 2022-12-19T06:19:55Z | - |
dc.date.available | 2022-12-19T06:19:55Z | - |
dc.date.issued | 2020-07-24 | - |
dc.identifier.citation | Wranke, A. vd. (2020). "Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta". Journal of Viral Hepatitis, 27(12), 1359-1368. | en_US |
dc.identifier.issn | 1352-0504 | - |
dc.identifier.uri | https://doi.org/10.1111/jvh.13366 | - |
dc.identifier.uri | https://onlinelibrary.wiley.com/doi/10.1111/jvh.13366 | - |
dc.identifier.uri | http://hdl.handle.net/11452/29943 | - |
dc.description.abstract | Hepatitis delta virus (HDV) infection causes the most severe form of viral hepatitis. PEG-interferon alpha-2a (PEG-IFNα-2a) is the only effective treatment but its long-term clinical impact is unclear. The aim of this study was to investigate the long-term outcome after 48 weeks of pegylated interferon alpha-2a therapy. We performed a retrospective follow-up study of the Hep-Net-International-Delta-Hepatitis-Intervention-Study 1 (HIDIT-I trial). Patients had received 48 weeks of treatment with either PEG-IFNα-2a plus adefovir dipivoxil (ADV) (Group I), PEG-IFNα-2a alone (Group II) or adefovir dipivoxil alone (Group III). Liver-related complications were defined as liver-related death, liver transplantation, liver cancer and hepatic decompensation defined as development of Child-Pugh scores B or C or an increase in Model for End-stage Liver Disease (MELD) scores of five or more points in relation to baseline values. Patients were considered for further analysis when they were retreated with PEG-IFNα-2a. Follow-up data (at least 1 visit beyond post-treatment week 24) were available for 60 patients [Group I, (n = 19), Group II (n = 20), Group III (n = 21)]. Mean time of follow-up was 8.9 (1.6 - 13.4) years. 19 patients were retreated with IFN-based therapy: 42% (n = 8) in PEG-IFNα-2a arms and 58% (n = 11) in the adefovir only arm. Clinical complications on long-term follow-up occurred in 17 patients and were associated with nonresponse to therapy and baseline cirrhosis. The annual event-free survival rate in patients with cirrhosis vs noncirrhotic patients at year 5 and 10 was 70% vs 91% and 35% vs 76%. Long-term follow-up of a large randomized clinical trial suggests that off-treatment HDV RNA response to PEG-IFNα-2a treatment leads to improved clinical long-term outcome. | en_US |
dc.description.sponsorship | German Liver Foundation | en_US |
dc.description.sponsorship | Deutsches Zentrum für Infektionsforschung | en_US |
dc.language.iso | en | en_US |
dc.publisher | Wiley | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Atıf Gayri Ticari Türetilemez 4.0 Uluslararası | tr_TR |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Chronic hepatitis | en_US |
dc.subject | Clinical outcome | en_US |
dc.subject | Delta virus | en_US |
dc.subject | Endpoint | en_US |
dc.subject | Hepatitis D | en_US |
dc.subject | Interferon therapy | en_US |
dc.subject | Virus-RNA | en_US |
dc.subject | Infection | en_US |
dc.subject | Prevalence | en_US |
dc.subject | Kinetics | en_US |
dc.subject | Alpha-2b | en_US |
dc.subject | Flares | en_US |
dc.subject | Need | en_US |
dc.subject | Gastroenterology & hepatology | en_US |
dc.subject | Infectious diseases | en_US |
dc.subject | Virology | en_US |
dc.subject.mesh | Antiviral agents | en_US |
dc.subject.mesh | Drug therapy, combination | en_US |
dc.subject.mesh | End stage liver disease | en_US |
dc.subject.mesh | Follow-up studies | en_US |
dc.subject.mesh | Hepatitis, chronic | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Polyethylene glycols | en_US |
dc.subject.mesh | Recombinant proteins | en_US |
dc.subject.mesh | Retrospective studies | en_US |
dc.subject.mesh | Severity of illness index | en_US |
dc.subject.mesh | Treatment outcome | en_US |
dc.title | Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000558543300001 | tr_TR |
dc.identifier.scopus | 2-s2.0-85089259771 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı. | tr_TR |
dc.identifier.startpage | 1359 | tr_TR |
dc.identifier.endpage | 1368 | tr_TR |
dc.identifier.volume | 27 | tr_TR |
dc.identifier.issue | 12 | tr_TR |
dc.relation.journal | Journal of Viral Hepatitis | en_US |
dc.contributor.buuauthor | Gürel, Selim | - |
dc.contributor.researcherid | EYK-5719-2022 | tr_TR |
dc.relation.collaboration | Yurt dışı | tr_TR |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.collaboration | Sanayi | tr_TR |
dc.identifier.pubmed | 32707605 | tr_TR |
dc.subject.wos | Gastroenterology & hepatology | en_US |
dc.subject.wos | Infectious diseases | en_US |
dc.subject.wos | Virology | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | PubMed | en_US |
dc.wos.quartile | Q2 | en_US |
dc.wos.quartile | Q3 (Gastroenterology & hepatology) | en_US |
dc.contributor.scopusid | 7003706434 | tr_TR |
dc.subject.scopus | Hepatitis Delta Virus; Chronic Hepatitis D; Hepatitis B | en_US |
dc.subject.emtree | Adefovir dipivoxil | en_US |
dc.subject.emtree | Alanine aminotransferase | en_US |
dc.subject.emtree | Albumin | en_US |
dc.subject.emtree | Alkaline phosphatase | en_US |
dc.subject.emtree | Aspartate aminotransferase | en_US |
dc.subject.emtree | Bilirubin | en_US |
dc.subject.emtree | Creatinine | en_US |
dc.subject.emtree | Gamma glutamyltransferase | en_US |
dc.subject.emtree | Hepatitis B surface antigen | en_US |
dc.subject.emtree | Peginterferon alpha2a | en_US |
dc.subject.emtree | Virus RNA | en_US |
dc.subject.emtree | Antivirus agent | en_US |
dc.subject.emtree | Macrogol | en_US |
dc.subject.emtree | Recombinant protein | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Alanine aminotransferase blood level | en_US |
dc.subject.emtree | Albumin blood level | en_US |
dc.subject.emtree | Alkaline phosphatase blood level | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Aspartate aminotransferase blood level | en_US |
dc.subject.emtree | Bilirubin blood level | en_US |
dc.subject.emtree | Child Pugh score | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Creatinine blood level | en_US |
dc.subject.emtree | Death | en_US |
dc.subject.emtree | Decompensated liver cirrhosis | en_US |
dc.subject.emtree | Delta agent hepatitis | en_US |
dc.subject.emtree | End stage liver disease | en_US |
dc.subject.emtree | Event free survival | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Follow up | en_US |
dc.subject.emtree | Gamma glutamyl transferase blood level | en_US |
dc.subject.emtree | General condition improvement | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Liver cancer | en_US |
dc.subject.emtree | Liver transplantation | en_US |
dc.subject.emtree | Major clinical study | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Retrospective study | en_US |
dc.subject.emtree | Treatment duration | en_US |
dc.subject.emtree | Treatment outcome | en_US |
dc.subject.emtree | Treatment refusal | en_US |
dc.subject.emtree | Treatment withdrawal | en_US |
dc.subject.emtree | Chronic hepatitis | en_US |
dc.subject.emtree | Combination drug therapy | en_US |
dc.subject.emtree | End stage liver disease | en_US |
dc.subject.emtree | Follow up | en_US |
dc.subject.emtree | Randomized controlled trial | en_US |
dc.subject.emtree | Severity of illness index | en_US |
dc.subject.emtree | Treatment outcome | en_US |
Appears in Collections: | PubMed Scopus Web of Science |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Gürel_vd_2020.pdf | 629.52 kB | Adobe PDF | ![]() View/Open |
This item is licensed under a Creative Commons License